Additionally, MYC and p53 pathways are deregulated in CML LSC regardless of the responsiveness to TKI treatment and, upon investigation, were shown not to be targeted by TKI [13]. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.